Mononuclear phagocytes play an important role in many pathological processes involving fibrin, and are ubiquitous cells in chronic inflammation. Numerous and intimate interactions occur between these cells and the coagulation system. Macrophages bind coagulation factors, promote clotting reactions, bind and degrade fibrin, and bind plasma proteins though to modulate these interactions. One such plasma protein is fibronectin which has discrete binding sites that are specific for ligands including fibrin, Factor XIIIa and cells. This adhesive glycoprotein is synthesized by marcophages and also enhances certain phagocytic activities of these cells. This proposal is concerned with the molecular basis for macrophage-fibronectin interactions, and particularly the cell surface molecule(s) responsible for binding this protein. Several lines of evidence suggest that the receptor for fibronectin is different than that of other cells (e.g., fibroblasts) and the major aim of research proposed is to identify this receptor in mononuclear phagocytes. Three independent but complementary approaches are proposed, including the fractionation of cells by affinity chromatography, the generation of anti-macrophage monoclonal antibodies, and the use of chemical cross-linking reagents. The properties of the receptor will be examined in detail using these methods in conjunction with phagosome isolation procedures. Experiments are proposed to study the properties of this cell surface receptor, to determine its relatedness to the fibroblast receptor, and to study it in monocytes, macrophages and cell lines. These experiments are expected to provide new insights into interactions between fibronectin and mononuclear phagocytes and provide a basis for understanding this interaction in pathological processes.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
1R01GM036812-01A1
Application #
3291326
Study Section
Cellular Biology and Physiology Subcommittee 1 (CBY)
Project Start
1986-12-01
Project End
1989-11-30
Budget Start
1986-12-01
Budget End
1987-11-30
Support Year
1
Fiscal Year
1987
Total Cost
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02215
Kubo, M; Van de Water, L; Plantefaber, L C et al. (2001) Fibrinogen and fibrin are anti-adhesive for keratinocytes: a mechanism for fibrin eschar slough during wound repair. J Invest Dermatol 117:1369-81
Coito, A J; Korom, S; Graser, E et al. (1998) Blockade of very late antigen-4 integrin binding to fibronectin in allograft recipients: I. Treatment with connecting segment-1 peptides prevents acute rejection by suppressing intragraft mononuclear cell accumulation, endothelial activation, and cytokine Transplantation 65:699-706
Coito, A J; Brown, L F; Peters, J H et al. (1997) Expression of fibronectin splicing variants in organ transplantation: a differential pattern between rat cardiac allografts and isografts. Am J Pathol 150:1757-72
Van de Water, L (1997) Mechanisms by which fibrin and fibronectin appear in healing wounds: implications for Peyronie's disease. J Urol 157:306-10
Coito, A J; Korom, S; Van de Water, L et al. (1997) Distinct fibronectin splicing variants: potential targets for therapeutic immunomodulation in organ allograft recipients. Transplant Proc 29:1060-1
Coito, A J; Binder, J; Brown, L F et al. (1995) TNF-alpha upregulates the expression of fibronectin in acutely rejecting rat cardiac allografts. Transplant Proc 27:463-5
Coito, A J; Binder, J; Brown, L F et al. (1995) Anti-TNF-alpha treatment down-regulates the expression of fibronectin and decreases cellular infiltration of cardiac allografts in rats. J Immunol 154:2949-58
Brown, L F; Olbricht, S M; Berse, B et al. (1995) Overexpression of vascular permeability factor (VPF/VEGF) and its endothelial cell receptors in delayed hypersensitivity skin reactions. J Immunol 154:2801-7
Detmar, M; Yeo, K T; Nagy, J A et al. (1995) Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. J Invest Dermatol 105:44-50
Dubin, D; Peters, J H; Brown, L F et al. (1995) Balloon catheterization induced arterial expression of embryonic fibronectins. Arterioscler Thromb Vasc Biol 15:1958-67

Showing the most recent 10 out of 16 publications